184 related articles for article (PubMed ID: 37766666)
1. Estimating the overall survival benefit of adjuvant chemo-endocrine therapy in women over age 50 with pT1-2N0 early stage breast cancer and 21-gene recurrence score ≥26: A National Cancer Database analysis.
Stabellini N; Cao L; Towe CW; Amin AL; Montero AJ
Cancer Med; 2023 Oct; 12(19):19607-19616. PubMed ID: 37766666
[TBL] [Abstract][Full Text] [Related]
2. Adjuvant chemotherapy is associated with an overall survival benefit regardless of age in ER+/HER2- breast cancer pts with 1-3 positive nodes and oncotype DX recurrence score 20 to 25: an NCDB analysis.
Stabellini N; Cao L; Towe CW; Luo X; Amin AL; Montero AJ
Front Oncol; 2023; 13():1115208. PubMed ID: 37168373
[TBL] [Abstract][Full Text] [Related]
3. Is Routine Recurrence Score Testing in Patients Older than 70 Years of Age Warranted? An Evaluation of the National Cancer Database After TAILORx.
Lee RM; Switchenko JM; Ho TB; Arciero CA; Bhave MA; Subhedar PD
Ann Surg Oncol; 2019 Oct; 26(10):3152-3158. PubMed ID: 31342377
[TBL] [Abstract][Full Text] [Related]
4. Practice patterns and outcomes for patients with node-negative hormone receptor-positive breast cancer and intermediate 21-gene Recurrence Scores.
Chen J; Wu X; Christos PJ; Formenti S; Nagar H
Breast Cancer Res; 2018 Apr; 20(1):26. PubMed ID: 29661221
[TBL] [Abstract][Full Text] [Related]
5. Adjuvant Chemotherapy in Premenopausal Patients With Hormone-Positive Breast Cancer With a Recurrence Score of 16-25: A Retrospective Analysis Using the National Cancer Database.
Ashok Kumar P; Wang D; Huang D; Sivapiragasam A
JCO Precis Oncol; 2024 Mar; 8():e2300390. PubMed ID: 38564683
[TBL] [Abstract][Full Text] [Related]
6. Breast carcinoma with an Oncotype Dx recurrence score <18: Rate of distant metastases in a large series with clinical follow-up.
Wen HY; Krystel-Whittemore M; Patil S; Pareja F; Bowser ZL; Dickler MN; Norton L; Morrow M; Hudis CA; Brogi E
Cancer; 2017 Jan; 123(1):131-137. PubMed ID: 27526056
[TBL] [Abstract][Full Text] [Related]
7. The 21-gene Recurrence Score® assay predicts distant recurrence in lymph node-positive, hormone receptor-positive, breast cancer patients treated with adjuvant sequential epirubicin- and docetaxel-based or epirubicin-based chemotherapy (PACS-01 trial).
Penault-Llorca F; Filleron T; Asselain B; Baehner FL; Fumoleau P; Lacroix-Triki M; Anderson JM; Yoshizawa C; Cherbavaz DB; Shak S; Roca L; Sagan C; Lemonnier J; Martin AL; Roché H
BMC Cancer; 2018 May; 18(1):526. PubMed ID: 29728098
[TBL] [Abstract][Full Text] [Related]
8. Impact of adjuvant endocrine therapy in older patients with comorbidities and estrogen receptor-positive, node-negative breast cancer-A National Cancer Database analysis.
Tamirisa N; Lin H; Shen Y; Shaitelman SF; Karuturi MS; Giordano SH; Babiera GV; Bedrosian I
Cancer; 2021 Jul; 127(13):2196-2203. PubMed ID: 33735487
[TBL] [Abstract][Full Text] [Related]
9. Management of HR+/HER2+ lobular breast cancer and trends do not mirror better outcomes.
Yaghi M; Bilani N; Dominguez B; Jabbal IS; Rivera C; Bou Zerdan M; Li H; Saravia D; Stone E; Nahleh Z
Breast; 2022 Aug; 64():112-120. PubMed ID: 35640346
[TBL] [Abstract][Full Text] [Related]
10. 21-Gene Recurrence Score and Locoregional Recurrence in Node-Positive/ER-Positive Breast Cancer Treated With Chemo-Endocrine Therapy.
Mamounas EP; Liu Q; Paik S; Baehner FL; Tang G; Jeong JH; Kim SR; Butler SM; Jamshidian F; Cherbavaz DB; Sing AP; Shak S; Julian TB; Lembersky BC; Wickerham DL; Costantino JP; Wolmark N
J Natl Cancer Inst; 2017 Jan; 109(4):. PubMed ID: 28122895
[TBL] [Abstract][Full Text] [Related]
11. Adjuvant Chemotherapy Guided by a 21-Gene Expression Assay in Breast Cancer.
Sparano JA; Gray RJ; Makower DF; Pritchard KI; Albain KS; Hayes DF; Geyer CE; Dees EC; Goetz MP; Olson JA; Lively T; Badve SS; Saphner TJ; Wagner LI; Whelan TJ; Ellis MJ; Paik S; Wood WC; Ravdin PM; Keane MM; Gomez Moreno HL; Reddy PS; Goggins TF; Mayer IA; Brufsky AM; Toppmeyer DL; Kaklamani VG; Berenberg JL; Abrams J; Sledge GW
N Engl J Med; 2018 Jul; 379(2):111-121. PubMed ID: 29860917
[TBL] [Abstract][Full Text] [Related]
12. Impact of the 21-gene recurrence score assay compared with standard clinicopathologic guidelines in adjuvant therapy selection for node-negative, estrogen receptor-positive breast cancer.
Partin JF; Mamounas EP
Ann Surg Oncol; 2011 Nov; 18(12):3399-406. PubMed ID: 21537874
[TBL] [Abstract][Full Text] [Related]
13. Prediction of chemotherapy benefit by EndoPredict in patients with breast cancer who received adjuvant endocrine therapy plus chemotherapy or endocrine therapy alone.
Sestak I; Martín M; Dubsky P; Kronenwett R; Rojo F; Cuzick J; Filipits M; Ruiz A; Gradishar W; Soliman H; Schwartzberg L; Buus R; Hlauschek D; Rodríguez-Lescure A; Gnant M
Breast Cancer Res Treat; 2019 Jul; 176(2):377-386. PubMed ID: 31041683
[TBL] [Abstract][Full Text] [Related]
14. Implications of the 21-gene recurrence score assay (Oncotype DX) on adjuvant treatment decisions in ER-positive early-stage breast cancer patients: experience of Kuwait Cancer Control Center.
Fayaz S; Eissa HE; Demian GA
J Egypt Natl Canc Inst; 2020 Mar; 32(1):13. PubMed ID: 32372329
[TBL] [Abstract][Full Text] [Related]
15. 21-Gene Recurrence Score for prognosis and prediction of taxane benefit after adjuvant chemotherapy plus endocrine therapy: results from NSABP B-28/NRG Oncology.
Mamounas EP; Tang G; Paik S; Baehner FL; Liu Q; Jeong JH; Kim SR; Butler SM; Jamshidian F; Cherbavaz DB; Sing AP; Shak S; Julian TB; Lembersky BC; Lawrence Wickerham D; Costantino JP; Wolmark N
Breast Cancer Res Treat; 2018 Feb; 168(1):69-77. PubMed ID: 29128898
[TBL] [Abstract][Full Text] [Related]
16. Chemotherapy refusal and subsequent survival in healthy older women with high genomic risk estrogen receptor-positive breast cancer.
White MJ; Kolbow M; Prathibha S; Praska C; Ankeny JS; LaRocca CJ; Jensen EH; Tuttle TM; Hui JYC; Marmor S
Breast Cancer Res Treat; 2023 Apr; 198(2):309-319. PubMed ID: 36692668
[TBL] [Abstract][Full Text] [Related]
17. The 21-gene recurrence score in node-positive, hormone receptor-positive, HER2-negative breast cancer: a cautionary tale from an NCDB analysis.
Weiser R; Haque W; Polychronopoulou E; Hatch SS; Kuo YF; Gradishar WJ; Klimberg VS
Breast Cancer Res Treat; 2021 Feb; 185(3):667-676. PubMed ID: 33070279
[TBL] [Abstract][Full Text] [Related]
18. Outcomes of HER2-positive non-metastatic breast cancer patients treated with anti-HER2 therapy without chemotherapy.
Nguy S; Wu SP; Oh C; Gerber NK
Breast Cancer Res Treat; 2021 Jun; 187(3):815-830. PubMed ID: 33590386
[TBL] [Abstract][Full Text] [Related]
19. 21-Gene Assay to Inform Chemotherapy Benefit in Node-Positive Breast Cancer.
Kalinsky K; Barlow WE; Gralow JR; Meric-Bernstam F; Albain KS; Hayes DF; Lin NU; Perez EA; Goldstein LJ; Chia SKL; Dhesy-Thind S; Rastogi P; Alba E; Delaloge S; Martin M; Kelly CM; Ruiz-Borrego M; Gil-Gil M; Arce-Salinas CH; Brain EGC; Lee ES; Pierga JY; Bermejo B; Ramos-Vazquez M; Jung KH; Ferrero JM; Schott AF; Shak S; Sharma P; Lew DL; Miao J; Tripathy D; Pusztai L; Hortobagyi GN
N Engl J Med; 2021 Dec; 385(25):2336-2347. PubMed ID: 34914339
[TBL] [Abstract][Full Text] [Related]
20. Clinical Outcomes in Early Breast Cancer With a High 21-Gene Recurrence Score of 26 to 100 Assigned to Adjuvant Chemotherapy Plus Endocrine Therapy: A Secondary Analysis of the TAILORx Randomized Clinical Trial.
Sparano JA; Gray RJ; Makower DF; Albain KS; Saphner TJ; Badve SS; Wagner LI; Kaklamani VG; Keane MM; Gomez HL; Reddy PS; Goggins TF; Mayer IA; Toppmeyer DL; Brufsky AM; Goetz MP; Berenberg JL; Mahalcioiu C; Desbiens C; Hayes DF; Dees EC; Geyer CE; Olson JA; Wood WC; Lively T; Paik S; Ellis MJ; Abrams J; Sledge GW
JAMA Oncol; 2020 Mar; 6(3):367-374. PubMed ID: 31566680
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
